8-K
filed May 12, 2023, 7:59 PM ET
ticker LRMR
CIK 0001374690
other material
confidence high
sentiment neutral
materiality 0.15
Larimar Therapeutics stockholders elect three Class III directors at 2023 annual meeting
Larimar Therapeutics, Inc.
- Elected Frank Thomas, Carole S. Ben-Maimon, and Joseph Truitt as Class III directors until 2026.
- Advisory say-on-pay vote approved with 35.5M votes for, 337.9K against.
- Ratified PricewaterhouseCoopers as independent auditor for FY2023 (40.8M for).
- Broker non-votes of ~4.9M on director elections and say-on-pay.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Larimar Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2022 at the 2023-05-09 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
Proposal 2 – Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2022. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers in 2022, as follows: Votes For Votes Against Abstentions Broker Non-Votes 35,507,612 337,895 55,741 4,876,931
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Larimar Therapeutics, Inc. shareholders approved Ratification of Independent Registered Public Accountant at the 2023-05-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
Proposal 3 – Ratification of Independent Registered Public Accountant. The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified, as follows: Votes For Votes Against Abstentions Broker Non-Votes 40,769,530 6,201 2,448 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Larimar Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-05-09 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-09
Exact text from the filing
Proposal 1 – Election of Class III Directors. Frank Thomas, Carole S. Ben-Maimon, M.D. and Joseph Truitt were elected to the Board of Directors of the Company as Class III directors to serve until the Company’s 2026 Annual Meeting of Stockholders and until their successors, if any, are duly elected and qualified or appointed, or their earlier death, resignation, or removal, as follows: Name Votes For Votes Withheld Broker Non-Votes Frank Thomas 27,741,876 8,159,372 4,876,931 Carole S. Ben-Maimon, M.D. 27,757,513 8,143,735 4,876,931 Joseph Truitt 27,378,190 8,523,058 4,876,931
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.